MONMOUTH JUNCTION, N.J., May 14, 2018 /PRNewswire/ -- CytoSorbents Corporation(NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb®blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has received European Union regulatory approval to expand the use of CytoSorb to reduce elevated bilirubin and myoglobin from blood.
CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться